Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
May 09, 2022 at 01:24 am
Share
Samil Pharmaceutical Co.,Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 1,302.37 million compared to KRW 401.52 million a year ago. Net income was KRW 335.8 million compared to KRW 608.44 million a year ago. Basic earnings per share from continuing operations was KRW 27 compared to KRW 49 a year ago. Basic earnings per share was KRW 27 compared to KRW 49 a year ago.
SAMIL PHARMACEUTICAL CO., LTD is a Korea-based company mainly engaged in the manufacture of medicines. The Companyâs products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The Company distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.
SAMIL PHARMACEUTICAL CO.,LTD 
